XML 44 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Revenue Recognition (Tables)
 6 Months Ended
Jun. 30, 2021
Revenue from Contract with Customer [Abstract]  
Summary of Contract Assets and Liabilities The following table summarizes the values of contract assets, capitalized commissions and contract liabilities (in thousands):
June 30, 2021December 31, 2020
Current pharma contract assets (1)
$1,842 $1,643 
Long-term pharma contract assets (2)
325 290 
Total pharma contract assets$2,167 $1,933 
Current pharma capitalized commissions (1)
$128 $185 
Long-term pharma capitalized commissions (2)
940 970 
Total pharma capitalized commissions$1,068 $1,155 
Current pharma contract liabilities$4,497 $4,029 
Long-term pharma contract liabilities (3)
794 712 
Total pharma contract liabilities$5,291 $4,741 
(1) Current pharma contract assets and Current pharma capitalized commissions are classified as other current assets on the Consolidated Balance Sheets.
(2) Long-term pharma contract assets and Long-term pharma capitalized commissions are classified as other assets on the Consolidated Balance Sheets.
(3) Long-term pharma contract liabilities are classified as other long-term liabilities on the Consolidated Balance Sheets.
Summary of Disaggregation of Revenue The following table details the disaggregation of revenue for both the Clinical and Pharma Services Segments (in thousands):
Three Months Ended June 30,Six Months Ended June 30,
2021202020212020
Clinical Services:
    Client direct billing$63,137 $45,244 $123,846 $99,535 
    Commercial Insurance20,528 15,148 39,102 37,142 
    Medicare and Medicaid17,484 13,541 34,634 30,024 
    Self-Pay256 (49)310 165 
Total Clinical Services $101,405 $73,884 $197,892 $166,866 
Pharma Services:20,319 13,093 39,365 26,141 
Total Revenue$121,724 $86,977 $237,257 $193,007